AlphaGrep UK Ltd’s Rhythm Pharmaceuticals RYTM Stock Holding History

AlphaGrep UK Ltd’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,509	Closed	-$269K	–	915
2025 Q4	$269K	Buy	+2,509	New	+$266K	0.09%	491

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

AlphaGrep UK Ltd's RYTM Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 2,509 shares — an estimated $269K sold.

AlphaGrep UK Ltd first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $269K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

AlphaGrep UK Ltd reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
AlphaGrep UK Ltd sold 2,509 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $269K.
AlphaGrep UK Ltd first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
AlphaGrep UK Ltd's Rhythm Pharmaceuticals position peaked at $269K in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.